Nobili E - Search Results

1

Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?

Di Nunno V, Gatto L, Fragomeno B, Cubelli M, Nobili E, Romano I, Santoni M, Pisconti S, Montironi R, Massari F. Di Nunno V, et al. Among authors: nobili e. Future Oncol. 2018 Dec;14(29):2997-2999. doi: 10.2217/fon-2018-0604. Epub 2018 Nov 9. Future Oncol. 2018. PMID: 30411632 Free article. No abstract available.

2

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma.

Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. Di Nunno V, et al. Among authors: nobili e. Anticancer Drugs. 2018 Aug;29(7):710-715. doi: 10.1097/CAD.0000000000000644. Anticancer Drugs. 2018. PMID: 29846249

3

Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.

Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Di Nunno V, et al. Among authors: nobili e. Clin Genitourin Cancer. 2020 Apr;18(2):e83-e90. doi: 10.1016/j.clgc.2019.08.007. Epub 2019 Aug 20. Clin Genitourin Cancer. 2020. PMID: 31753738

4

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.

Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. Mollica V, et al. Among authors: nobili e. Anticancer Drugs. 2018 Oct;29(9):911-913. doi: 10.1097/CAD.0000000000000663. Anticancer Drugs. 2018. PMID: 29916898

5

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Among authors: nobili e. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246

6

The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.

Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F. Ciccarese C, et al. Among authors: nobili e. Expert Rev Anticancer Ther. 2016 Jul;16(7):681-96. doi: 10.1080/14737140.2016.1192468. Epub 2016 Jun 7. Expert Rev Anticancer Ther. 2016. PMID: 27210425 Review.

7

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers.

Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A. Giunchi F, et al. Among authors: nobili e. Diagnostics (Basel). 2020 Dec 20;10(12):1109. doi: 10.3390/diagnostics10121109. Diagnostics (Basel). 2020. PMID: 33419298 Free PMC article.

8

Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G. Di Marco M, et al. Among authors: nobili e. Oncol Rep. 2010 May;23(5):1183-92. doi: 10.3892/or_00000749. Oncol Rep. 2010. PMID: 20372829 Review.

9

Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C. Ghedini P, et al. Among authors: nobili e. Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758. doi: 10.1007/s00259-017-3888-9. Epub 2017 Nov 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 29192364

10

Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?

Di Federico A, Nuvola G, Sisi M, Lenzi B, Nobili E, Campana D. Di Federico A, et al. Among authors: nobili e. Anticancer Drugs. 2020 Nov;31(10):1103-1105. doi: 10.1097/CAD.0000000000000987. Anticancer Drugs. 2020. PMID: 32826413

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page